Frontline Camrelizumab Plus Chemotherapy Improves Survival in Advanced Esophageal Squamous Cell Carcinoma
Camrelizumab in combination with chemotherapy demonstrated improved overall survival and progression-free survival and a manageable safety profile as frontline therapy compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.